Page last updated: 2024-11-04

dihydro-3-coumaric acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

dihydro-3-coumaric acid: intermediate in biosynthesis of dihydrophenanthrenes from phenylalanine [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-(3-hydroxyphenyl)propanoic acid : A monocarboxylic acid that is propionic acid carrying a 3-hydroxyphenyl substituent at C-3. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID91
CHEMBL ID134401
CHEBI ID1427
SCHEMBL ID65250
MeSH IDM0115961

Synonyms (71)

Synonym
nsc-39468
nsc39468
nsc33135
3-(m-hydroxyphenyl)propionic acid
benzenepropanoic acid, 3-hydroxy-
nsc-33135
hydrocinnamic acid, m-hydroxy-
.beta.-(3-hydroxyphenyl)propionic acid
.beta.-(m-hydroxyphenyl)propionic acid
3-hydroxyphenylpropionic acid
ai3-32395
einecs 210-692-8
nsc 33135
3-hydroxybenzenepropanoic acid
beta-(3-hydroxyphenyl)propionic acid
brn 1947445
nsc 39468
CHEBI:1427 ,
beta-(m-hydroxyphenyl)propionic acid
3-(3-hydroxy-phenyl)-propanoic acid
inchi=1/c9h10o3/c10-8-3-1-2-7(6-8)4-5-9(11)12/h1-3,6,10h,4-5h2,(h,11,12
3-(3-hydroxyphenyl)propanoic acid
3-(3-hydroxyphenyl)propionic acid
m-hydroxyphenylpropionic acid
621-54-5
3-hydroxyphenylpropanoate
dihydro-3-coumaric acid
CHEMBL134401
AKOS000172844
F2119-0005
m-hydroxy-hydrocinnamic acid
3-hydroxyhydrocinnamic acid
m-hydrocoumaric acid
4-10-00-00630 (beilstein handbook reference)
unii-fj68of1p7c
fj68of1p7c ,
FT-0602143
AM20040880
AN-651/40987637
S6074
SCHEMBL65250
3-hydroxydihydrocinnamic acid
3-hydroxy-benzenepropanoic acid
3-(3-hydroxyphenyl)-propionic acid
3-(3-hydroxy-phenyl)-propionic acid
3-(3'-hydroxyphenyl)propionic acid
mfcd00016554
SY022016
DS-1833
dihydro-m-coumaric acid
DTXSID00211154
3-(3-hydroxyphenyl)propionic acid, >=98.0% (qnmr)
CS-W005255
beta-(3-hydroxyphenyl)propionate
3-(3-hydroxy-phenyl)-propanoate
b-(m-hydroxyphenyl)propionate
3-hydroxydihydrocinnamate
b-(3-hydroxyphenyl)propionate
b-(m-hydroxyphenyl)propionic acid
3-hydroxybenzenepropanoate
b-(3-hydroxyphenyl)propionic acid
3-hydroxyphenylpropionate
dihydro-m-coumarate
m-hydroxy-hydrocinnamate
beta-(m-hydroxyphenyl)propionate
3-(m-hydroxyphenyl)propionate
Q10395558
3-(3-hydroxyphenyl)propanoicacid
HY-W005255
EN300-235651
Z317038038

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" Polymeric proanthocyanidins are poorly absorbed in the small intestine of humans, and exposure may result from metabolism to phenolic acids by colonic bacteria."( Supplementation with grape seed polyphenols results in increased urinary excretion of 3-hydroxyphenylpropionic Acid, an important metabolite of proanthocyanidins in humans.
Croft, KD; Hodgson, JM; Puddey, IB; Ward, NC, 2004
)
0.32
" There is limited information on the bioavailability and bioactivity of GSPE-derived phenolic acid in the brain."( Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization.
Cooper, BR; D'Arcy, BR; Dubner, L; Faith, J; Ferruzzi, MG; Ho, L; Janle, EM; Jannasch, AH; Lachcik, PJ; Levine, S; Ono, K; Pasinetti, GM; Wang, D; Williams, BA; Zhao, W, 2015
)
0.42
"We orally administered GSPE to rats and investigated the bioavailability of 12 phenolic acids known to be generated by microbiota metabolism of anthocyanidins."( Role of intestinal microbiota in the generation of polyphenol-derived phenolic acid mediated attenuation of Alzheimer's disease β-amyloid oligomerization.
Cooper, BR; D'Arcy, BR; Dubner, L; Faith, J; Ferruzzi, MG; Ho, L; Janle, EM; Jannasch, AH; Lachcik, PJ; Levine, S; Ono, K; Pasinetti, GM; Wang, D; Williams, BA; Zhao, W, 2015
)
0.42
" However, the bioavailability of cocoa flavanols is very low and their bioactivity in vivo seems to be greatly mediated by the derived phenolic metabolites formed by intestinal microbiota."( Colonic metabolites from flavanols stimulate nitric oxide production in human endothelial cells and protect against oxidative stress-induced toxicity and endothelial dysfunction.
Álvarez-Cilleros, D; Goya, L; Martín, MÁ; Ramos, S, 2018
)
0.48
" Its bioavailability is, however, low and, therefore, its metabolites could rather be responsible for this effect."( A Mixture of Phenolic Metabolites of Quercetin Can Decrease Elevated Blood Pressure of Spontaneously Hypertensive Rats Even in Low Doses.
Mladěnka, P; Najmanová, I; Pourová, J, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human xenobiotic metaboliteAny human metabolite produced by metabolism of a xenobiotic compound in humans.
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
monocarboxylic acidAn oxoacid containing a single carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (3)

PathwayProteinsCompounds
2-Oxopent-4-enoate Metabolism1725
2-Oxopent-4-enoate Metabolism 21725
Flavan-3-ol metabolic pathway070

Bioassays (14)

Assay IDTitleYearJournalArticle
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID89778Number of taste judgments per compound1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90541Bitter character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID89577Intensity calculated on a molar basis relative to a 0.25 M sucrose solution at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90886Sweet / Bitter character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90730Sour character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90708Salty character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90563Other taste character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID90909Sweet character at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID89747Intensity calculated on a weight basis relative to an 85500 ppm sucrose solution at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID89913Percentage of judgments reporting an aftertaste at a concentration of 252 ppm and character thereof; Bitter1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID89600Experimentally determined perceived intensity of compound at a concentration of 252 ppm (mean value)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Dihydrochalcone sweeteners. A study of the atypical temporal phenomena.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (42)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (9.52)18.7374
1990's4 (9.52)18.2507
2000's11 (26.19)29.6817
2010's17 (40.48)24.3611
2020's6 (14.29)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.12

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.12 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.93 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.12)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (4.76%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (95.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]